Dennis J Slamon

Title(s)Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Dennis J. Slamon holds the Bowyer Professor of Medical Oncology.

    Collapse Research 
    Collapse Research Activities and Funding
    ADVANCES IN HUMAN BREAST AND PROSTATE CANCER
    NIH R13CA085280Mar 10, 2000 - Mar 9, 2001
    Role: Principal Investigator
    CLINICAL CANCER RESEARCH DEVELOPMENT
    NIH K12CA001714Sep 30, 1992 - Aug 31, 1997
    Role: Principal Investigator
    SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE/BREAST CANCER
    NIH P20CA058197Sep 30, 1992 - Sep 29, 1995
    Role: Principal Investigator
    CLINICAL STUDIES OF BIOLOGICAL RESPONSE MODIFIERS
    NIH/NCI N01CM087289Sep 30, 1988 - Sep 29, 1993
    Role: Principal Investigator
    ONCOGENES IN PHYSIOLOGIC AND PATHOLOGIC STATES
    NIH R01CA036827Jul 1, 1984 - Jun 30, 1997
    Role: Principal Investigator
    Signal Transduction in Oncogenesis
    NIH P01CA032737Apr 1, 1982 - Jun 30, 2008
    Role: Principal Investigator
    Academic Training in Medical Oncology
    NIH T32CA009297Jun 1, 1979 - Jun 30, 2014
    Role: Co-Principal Investigator
    ACADEMIC TRAINING IN HEMATOLOGY
    NIH T32DK007285Jul 1, 1978 - Jun 30, 1994
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024 Mar 21; 390(12):1080-1091. Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Ruiz-Borrego M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A, Taran T, Hortobagyi G. PMID: 38507751.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    2. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. J Clin Oncol. 2024 Mar 20; 42(9):994-1000. Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS. PMID: 38252901; PMCID: PMC10950136.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers. Mol Cancer Ther. 2023 Dec 01; 22(12):1365-1375. O'Brien NA, McDermott MSJ, Zhang J, Gong KW, Lu M, Hoffstrom B, Luo T, Ayala R, Chau K, Liang M, Madrid AM, Donahue TR, Glaspy JA, Presta L, Slamon DJ. PMID: 37788341.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    4. Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol Cancer. 2023 Oct 30; 22(1):175. McDermott MSJ, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. PMID: 37915024; PMCID: PMC10614316.
      View in: PubMed   Mentions:    Fields:    
    5. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023 08 31; 25(1):103. Neven P, Fasching PA, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Zarate JP, Wang Y, Chakravartty A, Wang C, Slamon DJ. PMID: 37653397; PMCID: PMC10469877.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors. Clin Cancer Res. 2023 06 01; 29(11):2131-2143. McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong JJ, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. PMID: 36884217; PMCID: PMC10233360.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    7. Integrative transcriptomics and cell systems analyses reveal protective pathways controlled by Igfbp-3 in anthracycline-induced cardiotoxicity. FASEB J. 2023 06; 37(6):e22977. Chen J, Chapski DJ, Jong J, Awada J, Wang Y, Slamon DJ, Vondriska TM, Packard RRS. PMID: 37219486; PMCID: PMC10286824.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    8. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol. 2023; 15:17588359231178125. Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, Loi S, Visco F, Bee-Munteanu V, Afenjar K, Fresco R, Taran T, Chakravartty A, Zarate JP, Lteif A, Hortobagyi GN. PMID: 37275963; PMCID: PMC10233570.
      View in: PubMed   Mentions: 9  
    9. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. J Clin Oncol. 2023 03 20; 41(9):1638-1645. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. PMID: 36921335.
      View in: PubMed   Mentions: 4     Fields:    
    10. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. J Clin Oncol. 2023 03 10; 41(8):1501-1510. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. PMID: 36881998.
      View in: PubMed   Mentions: 1     Fields:    
    11. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol. 2023 02 01; 9(2):197-205. Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. PMID: 36454580; PMCID: PMC9716438.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    12. Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2023 03; 170:221-228. Davidson TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, Larson MC, Oberg AL, Provencher DM, Glaspy JA, Karlan BY, Slamon DJ, Konecny GE, Ray-Coquard IL. PMID: 36709663; PMCID: PMC10425916.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    13. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Res. 2023 01 11; 25(1):2. de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, Prat A, Lopez-Valverde V, Boulet T, Hurvitz SA. PMID: 36631725; PMCID: PMC9832665.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    14. Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. Clin Cancer Res. 2023 01 04; 29(1):40-49. Wainberg ZA, Singh AS, Konecny GE, McCann KE, Hecht JR, Goldman J, Chmielowski B, Finn RS, O'Brien N, Von Euw E, Price MM, Martinez D, Yonemoto L, Brennan M, Glaspy JA, Slamon DJ. PMID: 36136304.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    15. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. Cancers (Basel). 2022 Oct 15; 14(20). Swain SM, Macharia H, Cortes J, Dang C, Gianni L, Hurvitz SA, Jackisch C, Schneeweiss A, Slamon D, Valagussa P, du Toit Y, Heinzmann D, Knott A, Song C, Cortazar P. PMID: 36291835; PMCID: PMC9599862.
      View in: PubMed   Mentions: 6  
    16. Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. Oncologist. 2022 Oct 01; 27(10):811-821. Wander SA, O'Brien N, Litchfield LM, O'Dea D, Morato Guimaraes C, Slamon DJ, Goel S. PMID: 35917168; PMCID: PMC9526495.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    17. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clin Cancer Res. 2022 08 15; 28(16):3433-3442. Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, André F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean MJ, Turner NC. PMID: 35552673; PMCID: PMC9662922.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    18. Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies. Mol Cancer Ther. 2022 05 04; 21(5):751-761. O'Brien NA, Huang HKT, McDermott MSJ, Madrid AM, Luo T, Ayala R, Issakhanian S, Gong KW, Lu M, Zhang J, Slamon DJ. PMID: 35417017.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    19. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clin Cancer Res. 2022 05 02; 28(9):1854-1862. Peddi PF, Fasching PA, Liu D, Quinaux E, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Cunningham JM, Weinshilboum RM, Pienkowski T, Eiermann W, Martín M, Bee V, Wang X, Wang L, Yang E, Slamon DJ, Hurvitz SA. PMID: 35110416.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    20. Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. Clin Cancer Res. 2022 03 15; 28(6):1107-1116. García-Sáenz JÁ, Martínez-Jáñez N, Cubedo R, Jerez Y, Lahuerta A, González-Santiago S, Ferrer N, Ramos M, Alonso-Romero JL, Antón A, Carrasco E, Chen J, Neuwirth R, Galinsky K, Vincent S, Leonard EJ, Slamon D. PMID: 34980598.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    21. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. Gynecol Oncol. 2021 12; 163(3):465-472. Konecny GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, Ma S, Mahner S, Sehouli J, Fasching PA, Feisel-Schwickardi G, Poelcher M, Roman LD, Rody A, Karlan BY, Mullany SA, Chen H, Ray-Coquard IL, Provencher DM, Yachnin A, Cottu PH, Glaspy JA, Haluska P, Slamon DJ. PMID: 34642026.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    22. A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer. 2021 Oct 08; 7(1):134. Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching PA, Ejlertsen B, Yang EH, Glaspy JA, Slamon DJ. PMID: 34625570; PMCID: PMC8501074.
      View in: PubMed   Mentions: 12  
    23. Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4939. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. PMID: 34470810.
      View in: PubMed   Mentions: 1     Fields:    
    24. Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]. Ann Oncol. 2021 Oct; 32(10):1307. Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA. PMID: 34412950.
      View in: PubMed   Mentions:    Fields:    
    25. Cycling cancer persister cells arise from lineages with distinct programs. Nature. 2021 08; 596(7873):576-582. Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hütter JC, Hu B, Thakore PI, Tabaka M, Fulco CP, Colgan W, Cuevas BM, Hurvitz SA, Slamon DJ, Deik A, Pierce KA, Clish C, Hata AN, Zaganjor E, Lahav G, Politi K, Brugge JS, Regev A. PMID: 34381210; PMCID: PMC9209846.
      View in: PubMed   Mentions: 137     Fields:    Translation:HumansCells
    26. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021 08; 32(8):1015-1024. Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA. PMID: 34102253.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCTClinical Trials
    27. Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. PLoS One. 2021; 16(5):e0251163. Zoeller JJ, Press MF, Selfors LM, Dering J, Slamon DJ, Hurvitz SA, Brugge JS. PMID: 33951110; PMCID: PMC8099090.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    28. Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nat Cancer. 2021 04; 2(4):400-413. McNamara KL, Caswell-Jin JL, Joshi R, Ma Z, Kotler E, Bean GR, Kriner M, Zhou Z, Hoang M, Beechem J, Zoeller J, Press MF, Slamon DJ, Hurvitz SA, Curtis C. PMID: 34966897; PMCID: PMC8713949.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    29. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. PMID: 33536276; PMCID: PMC8628647.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    30. Frontiers in HER2-positive breast cancer in 2020. Curr Opin Obstet Gynecol. 2021 02 01; 33(1):48-52. Peddi PF, Slamon DJ. PMID: 33369581.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. Gynecol Oncol. 2021 02; 160(2):539-546. Fejzo MS, Chen HW, Anderson L, McDermott MS, Karlan B, Konecny GE, Slamon DJ. PMID: 33229045.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    32. Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat Commun. 2020 11 17; 11(1):5824. Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, Bosserman L, DiCarlo B, Kennedy A, Giuliano A, Calfa C, Molthrop D, Mani A, Chen HW, Dering J, Adams B, Kotler E, Press MF, Brugge JS, Curtis C, Slamon DJ. PMID: 33203854; PMCID: PMC7673127.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    33. Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell. 2020 12 14; 38(6):829-843.e4. Zhao W, Li J, Chen MM, Luo Y, Ju Z, Nesser NK, Johnson-Camacho K, Boniface CT, Lawrence Y, Pande NT, Davies MA, Herlyn M, Muranen T, Zervantonakis IK, von Euw E, Schultz A, Kumar SV, Korkut A, Spellman PT, Akbani R, Slamon DJ, Gray JW, Brugge JS, Lu Y, Mills GB, Liang H. PMID: 33157050; PMCID: PMC7738392.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    34. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res. 2020 08 14; 22(1):89. O'Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ. PMID: 32795346; PMCID: PMC7427086.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    35. Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Res Treat. 2020 Nov; 184(1):23-35. Finn RS, Cristofanilli M, Ettl J, Gelmon KA, Colleoni M, Giorgetti C, Gauthier E, Liu Y, Lu DR, Zhang Z, Bartlett CH, Slamon DJ, Turner NC, Rugo HS. PMID: 32783178; PMCID: PMC7568717.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    36. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020 Sep; 183(2):419-428. Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, Shparyk YV, Thummala A, Voitko N, Bananis E, McRoy L, Wilner K, Huang X, Kim S, Slamon DJ, Ettl J. PMID: 32683565; PMCID: PMC7383036.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    37. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clin Cancer Res. 2020 10 15; 26(20):5411-5423. Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, Leong HS, Chen S, Intermaggio MP, Gilks B, Nazeran TM, Volchek M, Elatre W, Bentley RC, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, Leong SCY, Liu G, Johnson D, Chen B, Group A, Alsop J, Banerjee SN, Behrens S, Bodelon C, Brand AH, Brinton L, Carney ME, Chiew YE, Cushing-Haugen KL, Cybulski C, Ennis D, Fereday S, Fortner RT, García-Donas J, Gentry-Maharaj A, Glasspool R, Goranova T, Greene CS, Haluska P, Harris HR, Hendley J, Hernandez BY, Herpel E, Jimenez-Linan M, Karpinskyj C, Kaufmann SH, Keeney GL, Kennedy CJ, Köbel M, Koziak JM, Larson MC, Lester J, Lewsley LA, Lissowska J, Lubinski J, Luk H, Macintyre G, Mahner S, McNeish IA, Menkiszak J, Nevins N, Osorio A, Oszurek O, Palacios J, Hinsley S, Pearce CL, Pike MC, Piskorz AM, Ray-Coquard I, Rhenius V, Rodriguez-Antona C, Sharma R, Sherman ME, De Silva D, Singh N, Sinn P, Slamon D, Song H, Steed H, Stronach EA, Thompson PJ, Toloczko A, Trabert B, Traficante N, Tseng CC, Widschwendter M, Wilkens LR, Winham SJ, Winterhoff B, Beeghly-Fadiel A, Benitez J, Berchuck A, Brenton JD, Brown R, Chang-Claude J, Chenevix-Trench G, deFazio A, Fasching PA, García MJ, Gayther SA, Goodman MT, Gronwald J, Henderson MJ, Karlan BY, Kelemen LE, Menon U, Orsulic S, Pharoah PDP, Wentzensen N, Wu AH, Schildkraut JM, Rossing MA, Konecny GE, Huntsman DG, Huang RY, Goode EL, Ramus SJ, Doherty JA, Bowtell DD, Anglesio MS. PMID: 32554541; PMCID: PMC7572656.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    38. Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply. N Engl J Med. 2020 06 04; 382(23):e85. Slamon DJ, Jerusalem G. PMID: 32492319.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 02 13; 382(7):597-609. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. PMID: 31825569.
      View in: PubMed   Mentions: 437     Fields:    Translation:Humans
    40. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020 02 06; 382(6):514-524. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G. PMID: 31826360.
      View in: PubMed   Mentions: 241     Fields:    Translation:HumansCTClinical Trials
    41. Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer. Clin Cancer Res. 2020 02 01; 26(3):566-580. Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana S, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ. PMID: 31615937; PMCID: PMC7498177.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    42. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. Clin Cancer Res. 2020 01 01; 26(1):110-121. Finn RS, Liu Y, Zhu Z, Martin M, Rugo HS, Diéras V, Im SA, Gelmon KA, Harbeck N, Lu DR, Gauthier E, Huang Bartlett C, Slamon DJ. PMID: 31527167.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    43. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Breast J. 2020 03; 26(3):368-375. Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. PMID: 31448513; PMCID: PMC7155112.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    44. Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. Br J Cancer. 2019 08; 121(4):318-324. Veitch ZW, Cescon DW, Denny T, Yonemoto LM, Fletcher G, Brokx R, Sampson P, Li SW, Pugh TJ, Bruce J, Bray MR, Slamon DJ, Mak TW, Wainberg ZA, Bedard PL. PMID: 31303643; PMCID: PMC6738068.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    45. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019 09 01; 37(25):2206-2216. Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. PMID: 31157583; PMCID: PMC6774816.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCTClinical Trials
    46. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 08 15; 25(16):5061-5068. Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. PMID: 31113840; PMCID: PMC6901027.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    47. Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. Lung Cancer. 2019 09; 135:104-109. Noor ZS, Goldman JW, Lawler WE, Telivala B, Braiteh F, DiCarlo BA, Kennedy K, Adams B, Wang X, Jones B, Slamon DJ, Garon EB. PMID: 31446981.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    48. Role for polo-like kinase 4 in mediation of cytokinesis. Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11309-11318. Press MF, Xie B, Davenport S, Zhou Y, Guzman R, Nolan GP, O'Brien N, Palazzolo M, Mak TW, Brugge JS, Slamon DJ. PMID: 31097597; PMCID: PMC6561306.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    49. Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. Mol Cancer Ther. 2019 06; 18(6):1115-1126. Zoeller JJ, Vagodny A, Taneja K, Tan BY, O'Brien N, Slamon DJ, Sampath D, Leverson JD, Bronson RT, Dillon DA, Brugge JS. PMID: 30962322; PMCID: PMC6758547.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    50. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. J Natl Cancer Inst. 2019 04 01; 111(4):419-430. Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. PMID: 30032196; PMCID: PMC6449170.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    51. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(3):617-625. Fasching PA, Gass P, Häberle L, Volz B, Hein A, Hack CC, Lux MP, Jud SM, Hartmann A, Beckmann MW, Slamon DJ, Erber R. PMID: 30868391.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    52. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. JAMA Oncol. 2019 03 01; 5(3):366-375. Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ. PMID: 30520947; PMCID: PMC6439848.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    53. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol. 2019 03; 20(3):361-370. Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M. PMID: 30709633; PMCID: PMC7050571.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    54. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019 Apr; 174(3):719-729. Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. PMID: 30632023; PMCID: PMC6438948.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCTClinical Trials
    55. Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis. Science. 2019 01 18; 363(6424):270-275. Welin ER, Ngamnithiporn A, Klatte M, Lapointe G, Pototschnig GM, McDermott MSJ, Conklin D, Gilmore CD, Tadross PM, Haley CK, Negoro K, Glibstrup E, Grünanger CU, Allan KM, Virgil SC, Slamon DJ, Stoltz BM. PMID: 30573544; PMCID: PMC7017906.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    56. Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Rep. 2018 11 27; 25(9):2617-2633. Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Palsgrove D, Conklin D, Kinose Y, White JR, Press MF, Drapkin R, Easwaran H, Baylin SB, Slamon D, Velculescu VE, Scharpf RB. PMID: 30485824; PMCID: PMC6481945.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    57. Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Ther Adv Med Oncol. 2018; 10:1758835918807339. Hurvitz S, Singh R, Adams B, Taguchi JA, Chan D, Dichmann RA, Castrellon A, Hu E, Berkowitz J, Mani A, DiCarlo B, Callahan R, Smalberg I, Wang X, Meglar I, Martinez D, Hobbs E, Slamon DJ. PMID: 30542377; PMCID: PMC6236634.
      View in: PubMed   Mentions: 16  
    58. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018 Nov 15; 379(20):1926-1936. Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M. PMID: 30345905.
      View in: PubMed   Mentions: 424     Fields:    Translation:HumansCTClinical Trials
    59. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer. 2018 Oct 11; 18(1):965. Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J. PMID: 30305055; PMCID: PMC6180577.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    60. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. Eur J Cancer. 2018 11; 104:21-31. Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, Masuda N, Verma S, Loi S, Colleoni M, Theall KP, Huang X, Liu Y, Bartlett CH. PMID: 30308388.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    61. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 09; 123:91-98. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. PMID: 30089602; PMCID: PMC6118115.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    62. BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition. JCO Precis Oncol. 2018; 2. Campos MP, Cohen M, Von Euw E, Velculescu V, Kujak JL, Conklin D, Hallberg D, Slamon DJ, Elvin J, Konecny GE. PMID: 31799491; PMCID: PMC6886743.
      View in: PubMed   Mentions: 5     Fields:    
    63. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018 08 20; 36(24):2465-2472. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G. PMID: 29860922.
      View in: PubMed   Mentions: 365     Fields:    Translation:HumansCTClinical Trials
    64. MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer. Mol Cancer Ther. 2018 07; 17(7):1430-1440. Koutsioumpa M, Chen HW, O'Brien N, Koinis F, Mahurkar-Joshi S, Vorvis C, Soroosh A, Luo T, Issakhanian S, Pantuck AJ, Georgoulias V, Iliopoulos D, Slamon DJ, Drakaki A. PMID: 29703843.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    65. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018 04 01; 29(4):888-894. Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. PMID: 29360932; PMCID: PMC5913649.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    66. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nat Commun. 2018 03 21; 9(1):1178. Fejzo MS, Sazonova OV, Sathirapongsasuti JF, Hallgrímsdóttir IB, Vacic V, MacGibbon KW, Schoenberg FP, Mancuso N, Slamon DJ, Mullin PM, 23andMe Research Team. PMID: 29563502; PMCID: PMC5862842.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    67. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Mol Cancer Ther. 2018 05; 17(5):897-907. O'Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, Mc Nulty A, Marchal C, Kalous O, von Euw E, Hurvitz S, Mockbee C, Slamon DJ. PMID: 29483214.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    68. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer. Clin Respir J. 2018 Jun; 12(6):2020-2028. Du Q, Yu R, Wang H, Yan D, Yuan Q, Ma Y, Slamon D, Hou D, Wang H, Wang Q. PMID: 29356386.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    69. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 01; 19(1):115-126. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. PMID: 29175149.
      View in: PubMed   Mentions: 180     Fields:    Translation:HumansCTClinical Trials
    70. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 2017 Jun 01; 3(6):767-773. Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, King K, Koski S, Mulder K, Hiller JP, Scarfe A, Spratlin J, Huang YJ, Khan-Wasti S, Chua N, Sawyer MB. PMID: 27737436; PMCID: PMC5824322.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    71. Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi. Genes Chromosomes Cancer. 2017 08; 56(8):589-597. Fejzo MS, Anderson L, Chen HW, Guandique E, Kalous O, Conklin D, Slamon DJ. PMID: 28316110.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    72. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2017 04 06; 169(2):361. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R. PMID: 28388418.
      View in: PubMed   Mentions: 58     Fields:    
    73. An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cells. Sci Rep. 2017 02 15; 7:42612. Jiang J, Zhao H, Shu W, Tian J, Huang Y, Song Y, Wang R, Li E, Slamon D, Hou D, Du X, Zhang L, Chen Y, Wang Q. PMID: 28198402; PMCID: PMC5309797.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    74. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell. 2017 02 13; 31(2):225-239. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. PMID: 28196595; PMCID: PMC5501076.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCells
    75. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 11 17; 375(20):1925-1936. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. PMID: 27959613.
      View in: PubMed   Mentions: 996     Fields:    Translation:HumansCTClinical Trials
    76. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. Mol Cancer Ther. 2017 01; 16(1):228-238. Press MF, Ellis CE, Gagnon RC, Grob TJ, Buyse M, Villalobos I, Liang Z, Wu S, Bang YJ, Qin SK, Chung HC, Xu J, Park JO, Jeziorski K, Afenjar K, Ma Y, Estrada MC, Robinson DM, Scherer SJ, Sauter G, Hecht JR, Slamon DJ. PMID: 27811012.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    77. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol. 2016 10 10; 34(29):3518-3528. Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ. PMID: 27573653; PMCID: PMC5074347.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    78. Cancer Research in the 21st Century. Ann Surg. 2016 10; 264(4):555-65. Economou JS, Slamon DJ, Ribas A, Phelps ME. PMID: 27537535.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    79. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016 06 28; 18(1):67. Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S, Kim ST, Huang X, Schnell P, Nadanaciva S, Bartlett CH, Slamon DJ. PMID: 27349747; PMCID: PMC4924326.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    80. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. J Clin Oncol. 2016 06 20; 34(18):2115-24. André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. PMID: 27091708.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCellsCTClinical Trials
    81. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr; 17(4):425-439. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. PMID: 26947331.
      View in: PubMed   Mentions: 687     Fields:    Translation:HumansCTClinical Trials
    82. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2016 Feb 25; 164(5):1073. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R. PMID: 27064190.
      View in: PubMed   Mentions: 40     Fields:    
    83. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016 Feb 09; 18(1):17. Finn RS, Aleshin A, Slamon DJ. PMID: 26857361; PMCID: PMC4746893.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansAnimals
    84. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2016 Feb 10; 34(5):443-51. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houé V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D. PMID: 26628478.
      View in: PubMed   Mentions: 313     Fields:    Translation:HumansCTClinical Trials
    85. Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J Immunother Cancer. 2015; 3:41. Lu NT, Raizer J, Gabor EP, Liu NM, Vu JQ, Slamon DJ, Barstis JL. PMID: 26380087; PMCID: PMC4570757.
      View in: PubMed   Mentions: 12     Fields:    
    86. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015 Aug 27; 162(5):974-86. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Buhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Mergoub T, Chan TA, Baylin SB, Strick R. PMID: 26317466; PMCID: PMC4556003.
      View in: PubMed   Mentions: 801     Fields:    Translation:HumansAnimalsCells
    87. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015 Jul; 16(7):816-29. Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. PMID: 26092818.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCTClinical Trials
    88. ADRM1-amplified metastasis gene in gastric cancer. Genes Chromosomes Cancer. 2015 Aug; 54(8):506-515. Fejzo MS, Anderson L, Chen HW, Anghel A, Zhuo J, Anchoori R, Roden R, Slamon DJ. PMID: 26052681.
      View in: PubMed   Mentions: 16     Fields:    
    89. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast. 2015 Jun; 24(3):182-90. Diéras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roché H, Sánchez-Rovira P, Pienkowski T, Seguí Palmer MÁ, Li A, Sun YN, Pickett CA, Slamon DJ. PMID: 25747197.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    90. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Res Treat. 2015 Feb; 149(3):669-80. Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ. PMID: 25663547.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    91. PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clin Cancer Res. 2015 May 01; 21(9):2065-74. Stern HM, Gardner H, Burzykowski T, Elatre W, O'Brien C, Lackner MR, Pestano GA, Santiago A, Villalobos I, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Nuciforo P, Bee V, Mackey J, Slamon DJ, Press MF. PMID: 25649019; PMCID: PMC4417419.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    92. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 2014 Dec 23; 16(6):3419. Spurdle AB, Couch FJ, Parsons MT, McGuffog L, Barrowdale D, Bolla MK, Wang Q, Healey S, Schmutzler R, Wappenschmidt B, Rhiem K, Hahnen E, Engel C, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Ellis S, Frost D, Platte R, Perkins J, Evans DG, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Scuvera G, Manoukian S, Bonanni B, Mariette F, Fortuzzi S, Viel A, Pasini B, Papi L, Varesco L, Balleine R, Nathanson KL, Domchek SM, Offitt K, Jakubowska A, Lindor N, Thomassen M, Jensen UB, Rantala J, Borg Å, Andrulis IL, Miron A, Hansen TV, Caldes T, Neuhausen SL, Toland AE, Nevanlinna H, Montagna M, Garber J, Godwin AK, Osorio A, Factor RE, Terry MB, Rebbeck TR, Karlan BY, Southey M, Rashid MU, Tung N, Pharoah PD, Blows FM, Dunning AM, Provenzano E, Hall P, Czene K, Schmidt MK, Broeks A, Cornelissen S, Verhoef S, Fasching PA, Beckmann MW, Ekici AB, Slamon DJ, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Chang-Claude J, Flesch-Janys D, Rudolph A, Seibold P, Aittomäki K, Muranen TA, Heikkilä P, Blomqvist C, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Olson JE, Pankratz VS, John EM, Whittemore AS, West DW, Hamann U, Torres D, Ulmer HU, Rüdiger T, Devilee P, Tollenaar RA, Seynaeve C, Van Asperen CJ, Eccles DM, Tapper WJ, Durcan L, Jones L, Peto J, dos-Santos-Silva I, Fletcher O, Johnson N, Dwek M, Swann R, Bane AL, Glendon G, Mulligan AM, Giles GG, Milne RL, Baglietto L, McLean C, Carpenter J, Clarke C, Scott R, Brauch H, Brüning T, Ko YD, Cox A, Cross SS, Reed MW, Lubinski J, Jaworska-Bieniek K, Durda K, Gronwald J, Dörk T, Bogdanova N, Park-Simon TW, Hillemanns P, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Burwinkel B, Marme F, Surovy H, Yang R, Anton-Culver H, Ziogas A, Hooning MJ, Collée JM, Martens JW, Tilanus-Linthorst MM, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Lindblom A, Margolin S, Joseph V, Robson M, Rau-Murthy R, González-Neira A, Arias JI, Zamora P, Benítez J, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Peterlongo P, Zaffaroni D, Barile M, Capra F, Radice P, Teo SH, Easton DF, Antoniou AC, Chenevix-Trench G, Goldgar DE, ABCTB Investigators, EMBRACE Group, GENICA Network, HEBON Group, kConFab Investigators. PMID: 25857409; PMCID: PMC4352262.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    93. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan; 16(1):25-35. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. PMID: 25524798.
      View in: PubMed   Mentions: 804     Fields:    Translation:HumansCTClinical Trials
    94. Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression. J Biol Chem. 2015 Feb 27; 290(9):5566-81. Drew BG, Hamidi H, Zhou Z, Villanueva CJ, Krum SA, Calkin AC, Parks BW, Ribas V, Kalajian NY, Phun J, Daraei P, Christofk HR, Hewitt SC, Korach KS, Tontonoz P, Lusis AJ, Slamon DJ, Hurvitz SA, Hevener AL. PMID: 25468909; PMCID: PMC4342471.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    95. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015 Feb 01; 33(4):304-11. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA. PMID: 25452441; PMCID: PMC4302212.
      View in: PubMed   Mentions: 284     Fields:    Translation:Humans
    96. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014 Oct; 106(10). Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL. PMID: 25269487; PMCID: PMC4271115.
      View in: PubMed   Mentions: 184     Fields:    Translation:HumansCells
    97. Pleiotrophin mediates hematopoietic regeneration via activation of RAS. J Clin Invest. 2014 Nov; 124(11):4753-8. Himburg HA, Yan X, Doan PL, Quarmyne M, Micewicz E, McBride W, Chao NJ, Slamon DJ, Chute JP. PMID: 25250571; PMCID: PMC4347246.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCellsPHPublic Health
    98. Value of primary tumor gene signatures in colon cancer when national quality standards are adhered to: preliminary results of an international prospective multicenter trial. Ann Surg Oncol. 2015 Feb; 22(2):535-42. Bilchik AJ, Wainberg ZA, Nissan A, Slamon DJ, Protic M, Avital I, Chen HW, Chen D, Sim M, Elashoff D, Stojadinovic A. PMID: 25190115.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    99. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. Br J Cancer. 2014 Oct 28; 111(9):1788-801. Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, Linnartz R, Zubel A, Slamon DJ, Finn RS. PMID: 25167228; PMCID: PMC4453732.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    100. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol Cancer. 2014 Jun 24; 13:157. McDermott MS, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. PMID: 24958351; PMCID: PMC4230643.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    101. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res. 2014 Jul 01; 20(13):3507-20. O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ. PMID: 24879796.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    102. Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer. Springerplus. 2014; 3:244. Hurvitz SA, Bosserman LD, Chan D, Hagenstad CT, Kass FC, Smith FP, Rodriguez GI, Childs BH, Slamon DJ. PMID: 24860718; PMCID: PMC4031367.
      View in: PubMed   Mentions: 1  
    103. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest. 2014 Jun; 124(6):2611-25. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. PMID: 24762435; PMCID: PMC4038562.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCells
    104. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res. 2014 Jun 01; 20(11):2947-58. Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, Konecny GE. PMID: 24727326; PMCID: PMC4138720.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    105. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. Breast Cancer Res Treat. 2014 May; 145(1):193-203. Fasching PA, Weihbrecht S, Haeberle L, Gasparyan A, Villalobos IE, Ma Y, Ekici AB, Wachter DL, Hartmann A, Beckmann MW, Slamon DJ, Press MF. PMID: 24682655.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    106. PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing. PLoS One. 2014; 9(2):e89464. Liu B, Tahk S, Yee KM, Yang R, Yang Y, Mackie R, Hsu C, Chernishof V, O'Brien N, Jin Y, Fan G, Lane TF, Rao J, Slamon D, Shuai K. PMID: 24586797; PMCID: PMC3933565.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    107. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014 Feb 15; 5(3):587-98. Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, Jones PA, Slamon DJ, Baylin SB, Zahnow CA, Ahuja N. PMID: 24583822; PMCID: PMC3996658.
      View in: PubMed   Mentions: 229     Fields:    Translation:HumansCellsCTClinical Trials
    108. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2014 Mar; 140(3):443-52. Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, Patel C, von Euw E, Black A, Michelakis ED, Dubinett SM, Slamon DJ. PMID: 24442098; PMCID: PMC3939783.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCellsCTClinical Trials
    109. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol. 2014 Feb; 132(2):334-42. Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D. PMID: 24368280.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    110. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Res Treat. 2013 Oct; 141(3):397-408. Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS. PMID: 24091768.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    111. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013 Aug; 33(8):2997-3004. Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF. PMID: 23898052.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    112. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist. 2013; 18(7):812-8. Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ, Translational Research in Oncology BCIRG 006 Trial Investigators. PMID: 23814044; PMCID: PMC3720634.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    113. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013 Jun; 12(6):1002-15. Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. PMID: 23729402; PMCID: PMC3963026.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    114. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology. 2013 May; 57(5):1838-46. Finn RS, Aleshin A, Dering J, Yang P, Ginther C, Desai A, Zhao D, von Euw E, Busuttil RW, Slamon DJ. PMID: 23299860.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    115. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013 Apr; 45(4):392-8, 398e1-2. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, Le Marchand L, Buring JE, Eccles D, Miron P, Fasching PA, Brauch H, Chang-Claude J, Carpenter J, Godwin AK, Nevanlinna H, Giles GG, Cox A, Hopper JL, Bolla MK, Wang Q, Dennis J, Dicks E, Howat WJ, Schoof N, Bojesen SE, Lambrechts D, Broeks A, Andrulis IL, Guénel P, Burwinkel B, Sawyer EJ, Hollestelle A, Fletcher O, Winqvist R, Brenner H, Mannermaa A, Hamann U, Meindl A, Lindblom A, Zheng W, Devillee P, Goldberg MS, Lubinski J, Kristensen V, Swerdlow A, Anton-Culver H, Dörk T, Muir K, Matsuo K, Wu AH, Radice P, Teo SH, Shu XO, Blot W, Kang D, Hartman M, Sangrajrang S, Shen CY, Southey MC, Park DJ, Hammet F, Stone J, Veer LJ, Rutgers EJ, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Peto J, Schrauder MG, Ekici AB, Beckmann MW, Dos Santos Silva I, Johnson N, Warren H, Tomlinson I, Kerin MJ, Miller N, Marme F, Schneeweiss A, Sohn C, Truong T, Laurent-Puig P, Kerbrat P, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Perez JI, Menéndez P, Müller H, Arndt V, Stegmaier C, Lichtner P, Lochmann M, Justenhoven C, Ko YD, Gene ENvironmental Interaction and breast CAncer (GENICA) Network, Muranen TA, Aittomäki K, Blomqvist C, Greco D, Heikkinen T, Ito H, Iwata H, Yatabe Y, Antonenkova NN, Margolin S, Kataja V, Kosma VM, Hartikainen JM, Balleine R, kConFab Investigators, Tseng CC, Berg DV, Stram DO, Neven P, Dieudonné AS, Leunen K, Rudolph A, Nickels S, Flesch-Janys D, Peterlongo P, Peissel B, Bernard L, Olson JE, Wang X, Stevens K, Severi G, Baglietto L, McLean C, Coetzee GA, Feng Y, Henderson BE, Schumacher F, Bogdanova NV, Labrèche F, Dumont M, Yip CH, Taib NA, Cheng CY, Shrubsole M, Long J, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Knight JA, Glendon G, Mulligan AM, Tollenaar RA, Seynaeve CM, Kriege M, Hooning MJ, van den Ouweland AM, van Deurzen CH, Lu W, Gao YT, Cai H, Balasubramanian SP, Cross SS, Reed MW, Signorello L, Cai Q, Shah M, Miao H, Chan CW, Chia KS, Jakubowska A, Jaworska K, Durda K, Hsiung CN, Wu PE, Yu JC, Ashworth A, Jones M, Tessier DC, González-Neira A, Pita G, Alonso MR, Vincent D, Bacot F, Ambrosone CB, Bandera EV, John EM, Chen GK, Hu JJ, Rodriguez-Gil JL, Bernstein L, Press MF, Ziegler RG, Millikan RM, Deming-Halverson SL, Nyante S, Ingles SA, Waisfisz Q, Tsimiklis H, Makalic E, Schmidt D, Bui M, Gibson L, Müller-Myhsok B, Schmutzler RK, Hein R, Dahmen N, Beckmann L, Aaltonen K, Czene K, Irwanto A, Liu J, Turnbull C, Familial Breast Cancer Study (FBCS), Rahman N, Meijers-Heijboer H, Uitterlinden AG, Rivadeneira F, Australian Breast Cancer Tissue Bank (ABCTB) Investigators, Olswold C, Slager S, Pilarski R, Ademuyiwa F, Konstantopoulou I, Martin NG, Montgomery GW, Slamon DJ, Rauh C, Lux MP, Jud SM, Bruning T, Weaver J, Sharma P, Pathak H, Tapper W, Gerty S, Durcan L, Trichopoulos D, Tumino R, Peeters PH, Kaaks R, Campa D, Canzian F, Weiderpass E, Johansson M, Khaw KT, Travis R, Clavel-Chapelon F, Kolonel LN, Chen C, Beck A, Hankinson SE, Berg CD, Hoover RN, Lissowska J, Figueroa JD, Chasman DI, Gaudet MM, Diver WR, Willett WC, Hunter DJ, Simard J, Benitez J, Dunning AM, Sherman ME, Chenevix-Trench G, Chanock SJ, Hall P, Pharoah PD, Vachon C, Easton DF, Haiman CA, Kraft P. PMID: 23535733; PMCID: PMC3771695.
      View in: PubMed   Mentions: 267     Fields:    Translation:Humans
    116. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 2013 Jun; 12(6):890-900. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ. PMID: 23493311; PMCID: PMC3681857.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    117. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):270-8. Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ. PMID: 23399957; PMCID: PMC3573351.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    118. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May; 12(5):632-42. Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, Shi MM, Yovine A, Slamon DJ. PMID: 23443805.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    119. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013 Feb; 138(1):99-108. Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. PMID: 23420271; PMCID: PMC3585916.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    120. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther. 2013 Apr; 12(4):509-19. Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS. PMID: 23395886.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    121. Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer. Int J Mol Sci. 2013 Feb 01; 14(2):3094-109. Fejzo MS, Anderson L, von Euw EM, Kalous O, Avliyakulov NK, Haykinson MJ, Konecny GE, Finn RS, Slamon DJ. PMID: 23377018; PMCID: PMC3588033.
      View in: PubMed   Mentions: 27     Fields:    
    122. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat. 2013 Feb; 137(3):755-66. Johnston SR, Gómez H, Stemmer SM, Richie M, Durante M, Pandite L, Goodman V, Slamon D. PMID: 23283526.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    123. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012 Dec; 10(12):1597-606. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. PMID: 23071104; PMCID: PMC3732195.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCells
    124. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 2012 Sep; 11(9):1978-87. Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS. PMID: 22761403.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    125. The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet. 2012 Sep 01; 21(17):3926-39. Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, Broeks A, van Leeuwen FE, van't Veer LJ, Udo R, Dunning AM, Greco D, Aittomäki K, Blomqvist C, Shah M, Nordestgaard BG, Flyger H, Hopper JL, Southey MC, Apicella C, Garcia-Closas M, Sherman M, Lissowska J, Seynaeve C, Huijts PE, Tollenaar RA, Ziogas A, Ekici AB, Rauh C, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Andrulis IL, Ozcelik H, Mulligan AM, Glendon G, Hall P, Czene K, Liu J, Chang-Claude J, Wang-Gohrke S, Eilber U, Nickels S, Dörk T, Schiekel M, Bremer M, Park-Simon TW, Giles GG, Severi G, Baglietto L, Hooning MJ, Martens JW, Jager A, Kriege M, Lindblom A, Margolin S, Couch FJ, Stevens KN, Olson JE, Kosel M, Cross SS, Balasubramanian SP, Reed MW, Miron A, John EM, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Chenevix-Trench G, kConFab Investigators, Lambrechts D, Dieudonne AS, Hatse S, van Limbergen E, Benitez J, Milne RL, Zamora MP, Pérez JI, Bonanni B, Peissel B, Loris B, Peterlongo P, Rajaraman P, Schonfeld SJ, Anton-Culver H, Devilee P, Beckmann MW, Slamon DJ, Phillips KA, Figueroa JD, Humphreys MK, Easton DF, Schmidt MK. PMID: 22532573; PMCID: PMC3412377.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    126. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012 Jun 15; 18(12):3478-86. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. PMID: 22504044; PMCID: PMC3821872.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    127. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene. 2013 Jan 31; 32(5):554-63. Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA. PMID: 22391567; PMCID: PMC3371315.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCells
    128. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer. 2012 Jan 14; 12:16. Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ, Finn RS. PMID: 22244160; PMCID: PMC3292503.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    129. Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol. 2012; 14(3-4):65-78. Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF. PMID: 23526579; PMCID: PMC3602729.
      View in: PubMed   Mentions: 16  
    130. Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance. J Clin Oncol. 2012 Feb 01; 30(4):357-61. Press MF, Gordon MA, Slamon DJ. PMID: 22203766; PMCID: PMC3269964.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    131. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 06; 365(14):1273-83. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research Group. PMID: 21991949; PMCID: PMC3268553.
      View in: PubMed   Mentions: 1021     Fields:    Translation:Humans
    132. Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. Mol Cancer Ther. 2011 Aug; 10(8):1500-8. Zhu M, Saxton RE, Ramos L, Chang DD, Karlan BY, Gasson JC, Slamon DJ. PMID: 21670235.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    133. Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK. Genes Chromosomes Cancer. 2011 Jun; 50(6):434-41. Fejzo MS, Ginther C, Dering J, Anderson L, Venkatesan N, Konecny G, Karlan B, Slamon DJ. PMID: 21432940.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    134. Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer. 2011 Feb; 50(2):95-112. Tap WD, Eilber FC, Ginther C, Dry SM, Reese N, Barzan-Smith K, Chen HW, Wu H, Eilber FR, Slamon DJ, Anderson L. PMID: 21117066.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    135. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 2011 Mar 15; 17(6):1591-602. Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ. PMID: 21278246; PMCID: PMC4598646.
      View in: PubMed   Mentions: 158     Fields:    Translation:HumansCells
    136. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol. 2011 Mar 01; 29(7):859-67. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. PMID: 21189395; PMCID: PMC3068060.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    137. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011 Jan 10; 29(2):149-56. Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ. PMID: 21115860.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCTClinical Trials
    138. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010 Oct 08; 330(6001):228-31. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. PMID: 20826764; PMCID: PMC3076894.
      View in: PubMed   Mentions: 637     Fields:    Translation:HumansCells
    139. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol Oncol. 2010 Nov; 119(2):337-44. Zhu M, Fejzo MS, Anderson L, Dering J, Ginther C, Ramos L, Gasson JC, Karlan BY, Slamon DJ. PMID: 20688362.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    140. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia. 2010 Aug; 12(8):637-49. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ. PMID: 20689758; PMCID: PMC2915408.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    141. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin Breast Cancer. 2010 Aug 01; 10(4):307-12. Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. PMID: 20705564.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    142. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther. 2010 Jul; 9(7):1985-94. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ. PMID: 20587667; PMCID: PMC2939826.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    143. FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 2010 Jul 01; 70(13):5475-85. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. PMID: 20551062; PMCID: PMC2896450.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    144. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther. 2010 Jun; 9(6):1489-502. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. PMID: 20501798.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansCells
    145. RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. Lung Cancer. 2010 Dec; 70(3):253-62. Oh JJ, Taschereau EO, Koegel AK, Ginther CL, Rotow JK, Isfahani KZ, Slamon DJ. PMID: 20338664.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    146. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010 Mar 01; 16(5):1509-19. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS. PMID: 20179222.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimalsCells
    147. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. 2010 Feb 04; 10:32. Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV. PMID: 20132554; PMCID: PMC2824712.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    148. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat. 2010 Apr; 120(2):481-9. Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ. PMID: 20130985.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    149. Tissue microarrays from frozen tissues-OCT technique. Methods Mol Biol. 2010; 664:73-80. Fejzo MS, Slamon DJ. PMID: 20690054.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    150. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer. 2009 Nov 17; 101(10):1699-708. Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ. PMID: 19861960; PMCID: PMC2778533.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    151. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat. 2010 Apr; 120(3):593-601. Xu J, Huo D, Chen Y, Nwachukwu C, Collins C, Rowell J, Slamon DJ, Olopade OI. PMID: 19466541; PMCID: PMC6697119.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    152. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst. 2009 May 06; 101(9):615-8. Slamon DJ, Press MF. PMID: 19401550.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    153. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009 May; 174(5):1597-601. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IeM. PMID: 19349352; PMCID: PMC2671248.
      View in: PubMed   Mentions: 183     Fields:    Translation:HumansCells
    154. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009 Mar 10; 27(8):1323-33. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. PMID: 19204209.
      View in: PubMed   Mentions: 176     Fields:    Translation:Humans
    155. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer. 2009 Feb; 9(1):16-22. Britten CD, Finn RS, Bosserman LD, Wong SG, Press MF, Malik M, Lum BL, Slamon DJ. PMID: 19299235; PMCID: PMC6042515.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    156. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009; 11(5):R77. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PMID: 19874578; PMCID: PMC2790859.
      View in: PubMed   Mentions: 647     Fields:    Translation:HumansCells
    157. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. Genes Chromosomes Cancer. 2008 Oct; 47(10):873-83. Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ. PMID: 18615678.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    158. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol. 2008 Jun 20; 26(18):2952-8. Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler HP, Karlan BY. PMID: 18565881.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    159. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer. 2008 Mar 25; 98(6):1076-84. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC. PMID: 18334972; PMCID: PMC2275492.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    160. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem. 2008 Apr 11; 283(15):9571-9. Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, Slamon DJ, Kwon O, Tamanoi F. PMID: 18230616; PMCID: PMC2442295.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    161. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res. 2008; 10(1):R3. Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, Vadgama JV. PMID: 18184439; PMCID: PMC2374954.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    162. Herceptin. Handb Exp Pharmacol. 2008; (181):183-219. Shepard HM, Jin P, Slamon DJ, Pirot Z, Maneval DC. PMID: 18071947.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    163. RIN1 is a breast tumor suppressor gene. Cancer Res. 2007 Dec 15; 67(24):11510-6. Milstein M, Mooser CK, Hu H, Fejzo M, Slamon D, Goodglick L, Dry S, Colicelli J. PMID: 18089779; PMCID: PMC2950063.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    164. Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus. Hum Genet. 2008 Feb; 123(1):55-64. Oh JJ, Boctor BN, Jimenez CA, Lopez R, Koegel AK, Taschereau EO, Phan DT, Jacobsen SE, Slamon DJ. PMID: 18038152.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    165. The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancers. Lung Cancer. 2007 Oct; 58(1):7-14. Oh JJ, Koegel AK, Phan DT, Razfar A, Slamon DJ. PMID: 17606309; PMCID: PMC2071930.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    166. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008 Mar; 61(3):515-24. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D. PMID: 17505827.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    167. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev. 2007 May; 16(5):1026-31. Jones LW, Haykowsky M, Peddle CJ, Joy AA, Pituskin EN, Tkachuk LM, Courneya KS, Slamon DJ, Mackey JR. PMID: 17507633.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    168. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer. 2007 04; 7(4):309-15. Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, Sledge G, Visco FM. PMID: 17384585.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    169. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res. 2007 Feb 15; 13(4):1238-45. Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. PMID: 17317835.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    170. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007 Nov; 105(3):319-26. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. PMID: 17268817.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCells
    171. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2786-92. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D. PMID: 16782917.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCTClinical Trials
    172. 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis. Cancer Res. 2006 Apr 01; 66(7):3419-27. Oh JJ, Razfar A, Delgado I, Reed RA, Malkina A, Boctor B, Slamon DJ. PMID: 16585163.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    173. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006 Apr 20; 24(12):1831-8. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ. PMID: 16549824.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    174. Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol. 2006 Mar; 4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. Slamon DJ, Romond EH, Perez EA, CME Consultants, Inc. PMID: 16736568.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    175. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006 Feb 01; 66(3):1630-9. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. PMID: 16452222.
      View in: PubMed   Mentions: 347     Fields:    Translation:HumansAnimalsCells
    176. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006 Apr; 17(4):597-604. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ. PMID: 16403812.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    177. Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer. 2005 Dec 20; 117(6):1049-54. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A. PMID: 15986428.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    178. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res. 2005; 7(6):R1058-79. Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ, Slamon DJ. PMID: 16457687; PMCID: PMC1410754.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    179. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005 Sep 15; 11(18):6598-607. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ. PMID: 16166438.
      View in: PubMed   Mentions: 104     Fields:    Translation:Humans
    180. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov; 16(11):1772-7. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. PMID: 16150805.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    181. Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways. J Natl Cancer Inst. 2005 Sep 07; 97(17):1238-9. Wilson CA, Slamon DJ. PMID: 16145037.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    182. Use of low-melting-point primers for bisulfite genomic sequencing: analysis of the H37 lung cancer tumor suppressor gene promoter. Anal Biochem. 2005 Aug 15; 343(2):347-9. Oh JJ, Boctor B, Jimenez CA, Lopez RC, Razfar A, Slamon DJ. PMID: 15992761.
      View in: PubMed   Mentions: 1     Fields:    Translation:Cells
    183. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6. Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. PMID: 16137435.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    184. Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemias. DNA Cell Biol. 2005 May; 24(5):311-6. Carlson A, Berkowitz JM, Browning D, Slamon DJ, Gasson JC, Yates KE. PMID: 15869408.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    185. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 2005; 7(4):R436-43. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F. PMID: 15987448; PMCID: PMC1175054.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    186. Spatial and temporal changes in the subcellular localization of the nuclear protein-tyrosine kinase, c-Fes. DNA Cell Biol. 2005 Apr; 24(4):225-34. Carlson A, Yates KE, Slamon DJ, Gasson JC. PMID: 15812239.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    187. EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer Biol Ther. 2004 Dec; 3(12):1243-9. Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC. PMID: 15611621.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    188. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 2004 Aug 04; 96(15):1141-51. Konecny GE, Thomssen C, Lück HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Möbus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Jänicke F, Slamon DJ. PMID: 15292386.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    189. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 2004 Jun 01; 10(11):3885-96. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ. PMID: 15173098.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimals
    190. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst. 2004 May 19; 96(10):759-69. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ. PMID: 15150304.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCellsCTClinical Trials
    191. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004 May 19; 96(10):739-49. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. PMID: 15150302.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansAnimalsCells
    192. Evaluation of H37, a candidate 3p21.3 tumor suppressor gene, as a therapeutic and diagnostic marker in lung cancer. Chest. 2004 May; 125(5 Suppl):102S-3S. Oh JJ, Fishbein MC, Boctor B, Jimenez CA, Lopez R, Slamon DJ. PMID: 15136438.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    193. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. PMID: 15020607.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansCTClinical Trials
    194. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004 Mar 01; 10(5):1706-16. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD. PMID: 15014023.
      View in: PubMed   Mentions: 98     Fields:    Translation:Humans
    195. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors. Oncologist. 2004; 9 Suppl 3:1-3. Slamon DJ. PMID: 15163840.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    196. Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention? J Natl Cancer Inst. 2003 Dec 17; 95(24):1813-5. Konecny GE, Wilson CA, Slamon DJ. PMID: 14679144.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    197. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003 Jan 15; 95(2):142-53. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. PMID: 12529347.
      View in: PubMed   Mentions: 149     Fields:    Translation:HumansCells
    198. Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif. 2003; 21:223-33. Finn RS, Slamon DJ. PMID: 15338747.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    199. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003 Jan 01; 63(1):196-206. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ. PMID: 12517798.
      View in: PubMed   Mentions: 179     Fields:    Translation:HumansCells
    200. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol. 2002 Nov; 87(2):200-6. Elkas JC, Baldwin RL, Pegram M, Tseng Y, Slamon D, Karlan BY. PMID: 12477452.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    201. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park). 2002 Nov; 16(11):1576, 1578. Konecny G, Slamon DJ. PMID: 12469932.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    202. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002 Jul 15; 20(14):3095-105. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. PMID: 12118023.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCells
    203. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 2002 Jul 15; 20(14):3106-13. Osoba D, Slamon DJ, Burchmore M, Murphy M. PMID: 12118024.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    204. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002 Jul; 9(7):553-66. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. PMID: 12082455.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCellsCTClinical Trials
    205. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 2002 Jul; 9(7):567-72. Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, Karlan B, Slamon D, Pegram M. PMID: 12082456.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    206. A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3. Cancer Res. 2002 Jun 01; 62(11):3207-13. Oh JJ, West AR, Fishbein MC, Slamon DJ. PMID: 12036935.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    207. Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. Exp Hematol. 2002 Apr; 30(4):374-80. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA. PMID: 11937274.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    208. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002 Mar; 1(2):117-23. Shawver LK, Slamon D, Ullrich A. PMID: 12086869.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansAnimals
    209. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002 Mar; 112(3):472-81. Namazie A, Alavi S, Olopade OI, Pauletti G, Aghamohammadi N, Aghamohammadi M, Gornbein JA, Calcaterra TC, Slamon DJ, Wang MB, Srivatsan ES. PMID: 12148857.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    210. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. PMID: 11821453.
      View in: PubMed   Mentions: 945     Fields:    Translation:HumansCTClinical Trials
    211. Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol. 2001 Nov; 159(5):1645-50. Schoenberg Fejzo M, Slamon DJ. PMID: 11696425; PMCID: PMC1867064.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    212. Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody. Clin Cancer Res. 2001 Jul; 7(7):2050-6. Bergman I, Barmada MA, Griffin JA, Slamon DJ. PMID: 11448923.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    213. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15; 344(11):783-92. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. PMID: 11248153.
      View in: PubMed   Mentions: 3308     Fields:    Translation:HumansCTClinical Trials
    214. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg. 2001 Mar; 88(3):412-8. Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS, Bundred NJ. PMID: 11260109.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    215. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:25-29. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. PMID: 11342197.
      View in: PubMed   Mentions: 19     Fields:    
    216. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. PMID: 11694786.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    217. Signal transduction : a technical overview. Methods Mol Med. 2001; 39:555-65. Arboleda MJ, Slamon DJ. PMID: 21340812.
      View in: PubMed   Mentions:    Fields:    
    218. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Genentech H0650 study investigators. PMID: 11167088.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    219. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol. 2000 Dec; 35(6):597-602. Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ. PMID: 11107126.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    220. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol. 2000 Dec; 27(6 Suppl 11):21-5; discussion 92-100. Pegram MD, Lopez A, Konecny G, Slamon DJ. PMID: 11236023.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    221. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000 Nov 01; 18(21):3651-64. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ. PMID: 11054438.
      View in: PubMed   Mentions: 130     Fields:    Translation:Humans
    222. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood. 2000 Oct 01; 96(7):2385-90. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA. PMID: 11001888.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    223. Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. Clin Cancer Res. 2000 Jul; 6(7):2931-40. Strawn LM, Kabbinavar F, Schwartz DP, Mann E, Shawver LK, Slamon DJ, Cherrington JM. PMID: 10914743.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    224. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res. 2000; 103:57-75. Pegram MD, Konecny G, Slamon DJ. PMID: 10948442.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimals
    225. A model-based approach for assessing in vivo combination therapy interactions. Proc Natl Acad Sci U S A. 1999 Nov 09; 96(23):13023-8. Lopez AM, Pegram MD, Slamon DJ, Landaw EM. PMID: 10557266; PMCID: PMC23893.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    226. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene. 1999 Oct 28; 18(44):6050-62. Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ. PMID: 10557094.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    227. Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res. 1999 Oct 15; 27(20):4008-17. Oh JJ, Grosshans DR, Wong SG, Slamon DJ. PMID: 10497265; PMCID: PMC148668.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    228. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999 Sep; 17(9):2639-48. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. PMID: 10561337.
      View in: PubMed   Mentions: 690     Fields:    Translation:HumansCTClinical Trials
    229. Biologic Approaches to Managing Advanced Breast Cancer. Cancer Control. 1999 Sep-Oct; 6(5 Suppl 2):7-11. Slamon D. PMID: 12118226.
      View in: PubMed   Mentions:    Fields:    
    230. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol. 1999 Aug; 26(4 Suppl 12):89-95. Pegram MD, Slamon DJ. PMID: 10482199.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    231. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999 Mar 15; 59(6):1347-55. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. PMID: 10096569.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    232. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 1999 Feb; 21(2):236-40. Wilson CA, Ramos L, Villaseñor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. PMID: 9988281.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansCells
    233. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol. 1999; 125(2):61-70. Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ. PMID: 10190311.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    234. Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media. J Hematother. 1998 Dec; 7(6):481-91. Paquette RL, Gonzales E, Yoshimura R, Tran L, Choi R, Baldwin G, Slamon DJ, Glaspy J. PMID: 9919941.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    235. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 1998 Oct 29; 17(17):2235-49. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. PMID: 9811454.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansAnimalsCells
    236. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998 Aug; 16(8):2659-71. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. PMID: 9704716.
      View in: PubMed   Mentions: 196     Fields:    Translation:HumansCTClinical Trials
    237. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998 Jun 01; 17(11):3052-65. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD. PMID: 9606188; PMCID: PMC1170645.
      View in: PubMed   Mentions: 415     Fields:    Translation:HumansAnimalsCells
    238. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol. 1998 Apr 01; 160(7):3419-26. Challita-Eid PM, Penichet ML, Shin SU, Poles T, Mosammaparast N, Mahmood K, Slamon DJ, Morrison SL, Rosenblatt JD. PMID: 9531302.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    239. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. Biochemistry. 1998 Mar 03; 37(9):3220-8. Landgraf R, Pegram M, Slamon DJ, Eisenberg D. PMID: 9485477.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    240. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 1998; 52(1-3):65-77. Pegram MD, Pauletti G, Slamon DJ. PMID: 10066073.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    241. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997 Aug; 15(8):2894-904. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. PMID: 9256133.
      View in: PubMed   Mentions: 176     Fields:    Translation:Humans
    242. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 1997 Jul 31; 15(5):537-47. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. PMID: 9247307.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    243. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene. 1997 Jan 09; 14(1):1-16. Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese DM, Slamon DJ, Calzone FJ. PMID: 9010228.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    244. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 1997; 15(1):1-8. Reese DM, Slamon DJ. PMID: 9007217.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    245. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 1996 Nov 07; 13(9):1971-81. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ. PMID: 8934544.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    246. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996 Jul 04; 13(1):63-72. Pauletti G, Godolphin W, Press MF, Slamon DJ. PMID: 8700555.
      View in: PubMed   Mentions: 120     Fields:    Translation:Humans
    247. 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts. Cancer Biother Radiopharm. 1996 Apr; 11(2):133-44. Kotts CE, Su FM, Leddy C, Dodd T, Scates S, Shalaby MR, Wirth CM, Giltinan D, Schroff RW, Fritzberg AR, Shepard HM, Slamon DJ, Hutchins BM. PMID: 10851530.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    248. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene. 1995 Oct 05; 11(7):1261-9. Levin WJ, Press MF, Gaynor RB, Sukhatme VP, Boone TC, Reissmann PT, Figlin RA, Holmes EC, Souza LM, Slamon DJ. PMID: 7478546.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    249. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995 Jun 15; 10(12):2435-46. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. PMID: 7784095.
      View in: PubMed   Mentions: 156     Fields:    Translation:HumansAnimalsCells
    250. Human c-FES is a nuclear tyrosine kinase. Oncogene. 1995 Mar 16; 10(6):1239-42. Yates KE, Lynch MR, Wong SG, Slamon DJ, Gasson JC. PMID: 7700650.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    251. Tumor suppressor and immediate early transcription factor genes in non-small cell lung cancer. Chest. 1994 Dec; 106(6 Suppl):372S-376S. Levin WJ, Casey G, Ramos JC, Arboleda MJ, Reissmann PT, Slamon DJ. PMID: 7988267.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    252. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994 Nov 01; 54(21):5675-82. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG, et al. PMID: 7522962.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    253. p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol. 1994 Sep; 7(7):766-70. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP. PMID: 7824511.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    254. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994 Jul; 9(7):1829-38. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. PMID: 7911565.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansAnimalsCells
    255. Proto-oncogenes and tumor suppressor genes in human urological malignancies. J Urol. 1994 Jun; 151(6):1479-97. Strohmeyer TG, Slamon DJ. PMID: 8189554.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    256. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994 May 15; 54(10):2771-7. Press MF, Hung G, Godolphin W, Slamon DJ. PMID: 7909495.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    257. Mutations of the p53 gene are not detectable in human testicular tumors. Mod Pathol. 1994 May; 7(4):435-9. Fleischhacker M, Strohmeyer T, Imai Y, Slamon DJ, Koeffler HP. PMID: 8066072.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    258. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol Oncol. 1994 Apr; 53(1):70-7. Karlan BY, Jones J, Slamon DJ, Lagasse LD. PMID: 7909787.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    259. Identification of conserved amino acids in the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit critical for function. Evidence for formation of a heterodimeric receptor complex prior to ligand binding. J Biol Chem. 1994 Jan 07; 269(1):277-83. Ronco LV, Silverman SL, Wong SG, Slamon DJ, Park LS, Gasson JC. PMID: 8276807.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    260. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene. 1993 Jul; 8(7):1913-9. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C, Slamon DJ. PMID: 8390038.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    261. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol. 1993 May; 11(5):891-8. Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ, Howell SB. PMID: 8098058.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    262. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene. 1993 Apr; 8(4):855-65. Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, Stram D, Slamon DJ, Steeg PS. PMID: 8384356.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    263. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene. 1992 Sep; 7(9):1859-66. Chazin VR, Kaleko M, Miller AD, Slamon DJ. PMID: 1354348.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    264. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treat Res. 1992; 61:193-211. Park JW, Stagg R, Lewis GD, Carter P, Maneval D, Slamon DJ, Jaffe H, Shepard HM. PMID: 1360232.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    265. A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases. Cancer. 1991 Sep 15; 68(6):1296-302. Tanaka T, Slamon DJ, Shimada H, Shimoda H, Fujisawa T, Ida N, Seeger RC. PMID: 1873783.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    266. Biological correlation between HER-2/neu and proliferative activity in human breast cancer. Anticancer Res. 1991 Jul-Aug; 11(4):1395-400. Tommasi S, Paradiso A, Mangia A, Barletta A, Simone G, Slamon DJ, De Lena M. PMID: 1684096.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    267. Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res. 1991 Apr 01; 51(7):1811-6. Strohmeyer T, Peter S, Hartmann M, Munemitsu S, Ackermann R, Ullrich A, Slamon DJ. PMID: 1706218.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    268. Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. Int J Cancer. 1991 Jan 02; 47(1):66-71. Giovanella BC, Vardeman DM, Williams LJ, Taylor DJ, de Ipolyi PD, Greeff PJ, Stehlin JS, Ullrich A, Cailleau R, Slamon DJ, et al. PMID: 1985881.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    269. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990 Jul; 5(7):953-62. Press MF, Cordon-Cardo C, Slamon DJ. PMID: 1973830.
      View in: PubMed   Mentions: 165     Fields:    Translation:Humans
    270. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res. 1990 Jul 01; 50(13):3947-51. Read LD, Keith D, Slamon DJ, Katzenellenbogen BS. PMID: 1972345.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    271. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990 Mar 15; 45(3):457-61. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. PMID: 1968437.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    272. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med. 1990 Feb; 114(2):164-9. Bacus SS, Bacus JW, Slamon DJ, Press MF. PMID: 1967930.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    273. Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest. 1990; 8(2):253. Slamon DJ. PMID: 1976032.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    274. HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res. 1990; 354A:209-21. Press MF, Jones LA, Godolphin W, Edwards CL, Slamon DJ. PMID: 1978943.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    275. Detection of anti-HTLV-I Tax antibodies in HTLV-I enzyme-linked immunosorbent assay-negative individuals. Blood. 1989 Aug 15; 74(3):1066-72. Ehrlich GD, Glaser JB, Abbott MA, Slamon DJ, Keith D, Sliwkowski M, Brandis J, Keitelman E, Teramoto Y, Papsidero L, et al. PMID: 2752152.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    276. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12; 244(4905):707-12. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. PMID: 2470152.
      View in: PubMed   Mentions: 1825     Fields:    Translation:HumansAnimalsCells
    277. Expression of protooncogene c-myb in normal human hematopoietic cells. Blood. 1989 May 01; 73(6):1444-51. Kastan MB, Slamon DJ, Civin CI. PMID: 2469491.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    278. Amplification of c-erbB-2 and aggressive human breast tumors? Science. 1988 Jun 24; 240(4860):1795-8. Slamon DJ, Clark GM. PMID: 3289120.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    279. HTLV-II transactivation is regulated by the overlapping tax/rex nonstructural genes. Science. 1988 May 13; 240(4854):916-9. Rosenblatt JD, Cann AJ, Slamon DJ, Smalberg IS, Shah NP, Fujii J, Wachsman W, Chen IS. PMID: 2834826.
      View in: PubMed   Mentions: 30     Fields:    Translation:Cells
    280. Subnuclear localization of the trans-activating protein of human T-cell leukemia virus type I. J Virol. 1988 Mar; 62(3):680-6. Slamon DJ, Boyle WJ, Keith DE, Press MF, Golde DW, Souza LM. PMID: 2828664; PMCID: PMC253620.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    281. Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. Prog Clin Biol Res. 1988; 271:57-69. Wada RK, Seeger RC, Brodeur GM, Slamon DJ, Rayner SA, Tomayko M, Reynolds CP. PMID: 3406020.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    282. Oncogenes in clinical cancer--a panel discussion. Breast Cancer Res Treat. 1987 Dec; 10(3):217-27. McGuire WL, Johnson BE, Seeger RC, Slamon DJ. PMID: 2833962.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    283. HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes. Science. 1987 Feb 06; 235(4789):674-7. Wachsman W, Cann AJ, Williams JL, Slamon DJ, Souza L, Shah NP, Chen IS. PMID: 3027894.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    284. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 09; 235(4785):177-82. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. PMID: 3798106.
      View in: PubMed   Mentions: 3426     Fields:    Translation:HumansCells
    285. Comparison of the trans-activation capabilities of the human T-cell leukemia virus type I and II chi proteins. Mol Cell Biol. 1986 Nov; 6(11):3626-31. Shah NP, Wachsman W, Cann AJ, Souza L, Slamon DJ, Chen IS. PMID: 3025604; PMCID: PMC367123.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    286. Regulation of expression of human granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci U S A. 1986 Nov; 83(22):8669-73. Chan JY, Slamon DJ, Nimer SD, Golde DW, Gasson JC. PMID: 3490669; PMCID: PMC386992.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    287. Studies of the human c-myb gene and its product in human acute leukemias. Science. 1986 Jul 18; 233(4761):347-51. Slamon DJ, Boone TC, Murdock DC, Keith DE, Press MF, Larson RA, Souza LM. PMID: 3014652.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    288. Identification and characterization of the protein encoded by the human N-myc oncogene. Science. 1986 May 09; 232(4751):768-72. Slamon DJ, Boone TC, Seeger RC, Keith DE, Chazin V, Lee HC, Souza LM. PMID: 3008339.
      View in: PubMed   Mentions: 36     Fields:    Translation:AnimalsCells
    289. The x gene is essential for HTLV replication. Science. 1985 Jul 05; 229(4708):54-8. Chen IS, Slamon DJ, Rosenblatt JD, Shah NP, Quan SG, Wachsman W. PMID: 2990037.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    290. Studies of the putative transforming protein of the type I human T-cell leukemia virus. Science. 1985 Jun 21; 228(4706):1427-30. Slamon DJ, Press MF, Souza LM, Murdock DC, Cline MJ, Golde DW, Gasson JC, Chen IS. PMID: 2990027.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    291. Identification of new gene products coded from X regions of human T-cell leukemia viruses. Proc Natl Acad Sci U S A. 1985 Jan; 82(2):302-6. Shimotohno K, Miwa M, Slamon DJ, Chen IS, Hoshino H, Takano M, Fujino M, Sugimura T. PMID: 2982148; PMCID: PMC397025.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    292. Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science. 1984 Oct 05; 226(4670):61-5. Slamon DJ, Shimotohno K, Cline MJ, Golde DW, Chen IS. PMID: 6089351.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCells
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Dennis's Networks
    Concepts (864)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (89)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California